LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or the “Company”), a clinical-stage immuno-oncology company historical...
Are there any disclosed risks or uncertainties (e.g., regulatory, clinical, financing) that could affect the stock's downside risk?
What is the expected impact of the announced corporate update on analyst sentiment and target price revisions?
What is the outlook for the company's pipeline beyond the Gammabody platform (e.g., additional candidates, platform extensions)?
25 days ago